Plasma biomarkers for Alzheimers disease: Much needed but tough to find

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 441-454

  Bazenet, Chantal ^a,b   Lovestone, Simon ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alzheimer; biomarkers; diagnosis; endophenotypes; metabolomics; plasma; progression; proteomics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; MICRORNA; PROTEOME; STEROL; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIPIDOMICS; METABOLOMICS; PREDICTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; BLOOD; METABOLISM; METHODOLOGY; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; METABOLOMICS; PEPTIDE FRAGMENTS; PROTEOMICS; RESEARCH DESIGN;

EID: 84865512129     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.48     Document Type: Review

References (98)

1. Thies W, Bleiler L. 2012 Alzheimer's disease facts and figures. Alzheimer's Demen. 8, 131-168 (2012).
2. Van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J. Alzheimers Dis. 20(3), 881-891 (2010).
3. Hampel H, Frank R, Broich K et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9(7), 560-574 (2010).
4. Broich K, Weiergraber M, Hampel H. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. Prog. Neurobiol. 95(4), 498-500 (2011).
5. Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exp. Gerontol. 45(1), 5-14 (2010).
6. Gomez Ravetti M, Rosso OA, Berretta R, Moscato P. Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One 5(4), e10153 (2010).
7. Hampel H, Wilcock G, Andrieu S et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 95(4), 579-593 (2011).
8. Ward M. Biomarkers for Alzheimer's disease. Expert Rev. Mol. Diagn. 7(5), 635-646 (2007). (Pubitemid 47547728)
9. Johnstone D, Milward EA, Berretta R, Moscato P. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) plasma proteome dataset. PLoS One 7(4), e34341 (2012).
10. Aisen PS. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol. Aging 32(Suppl. 1), S64-S66 (2011).
11. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6(3), 131-144 (2010).
12. Hampel H, Prvulovic D. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. J. Nutr. Health Aging 16(4), 346-348 (2012).
13. Hampel H, Shen Y, Walsh DM et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp. Neurol. 223(2), 334-346 (2010).
14. Morris JC, Selkoe DJ. Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiol. Aging 32(Suppl. 1), S1-S3 (2011).
15. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45(1), 30-40 (2010).
16. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5(3), 228-234 (2006). (Pubitemid 43238346)
17. Mulder C, Verwey NA, Van der Flier WM et al. Amyloid-beta (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 56(2), 248-253 (2010).
18. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118(1), 103-113 (2009).
19. Querfurth HW, LaFerla FM. Alzheimer's disease. N. Engl. J. Med. 362(4), 329-344 (2010).
20. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and metaanalysis. Arch. Neurol. 7(4 Suppl.), S318 (2012). Very good systematic review and analysis of the role and utility of plasma b-amyloid as a biomarker.
21. Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J. Neural. Transm. 119(7), 843-850 (2012).
22. Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Abeta40 and Abeta 42, and genetic variants. Neurobiol. Aging 32(Suppl. 1), S10-S19 (2011).
23. Ertekin-Taner N, Younkin LH, Yager DM et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70(8), 596-606 (2008). (Pubitemid 351294637)
24. Schupf N, Tang MX, Fukuyama H et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl Acad. Sci. USA 105(37), 14052-14057 (2008).
25. Assini A, Cammarata S, Vitali A et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63(5), 828-831 (2004). (Pubitemid 39297642)
26. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 60(7), 958-964 (2003). (Pubitemid 36858355)
27. Sundelof J, Giedraitis V, Irizarry MC et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch. Neurol. 65(2), 256-263 (2008). (Pubitemid 351240790)
28. Xia W, Yang T, Shankar G et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch. Neurol. 66(2), 190-199 (2009).
29. Taurines R, Dudley E, Grassl J et al. Proteomic research in psychiatry. J. Psychopharmacol. 25(2), 151-196 (2011). Comprehensive review of proteomics approaches and their utility in psychiatric research.
30. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359-1362 (2007). (Pubitemid 350073592)
31. O'Bryant SE, Xiao G, Barber R et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch. Neurol. 67(9), 1077-1081 (2010).
32. O'Bryant SE, Xiao G, Barber R et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One 6(12), e28092 (2011).
33. O'Bryant SE, Xiao G, Barber R et al. A blood-based algorithm for the detection of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 32(1), 55-62 (2011).
34. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(Pt 11), 3042-3050 (2006). First large plasma biomarker study. (Pubitemid 44684524)
35. Akuffo EL, Davis JB, Fox SM et al. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13(6), 618-636 (2008).
36. Cutler P, Akuffo EL, Bodnar WM et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl. 2(4), 467-477 (2008). (Pubitemid 351566256)
37. Lukiw WJ, Alexandrov PN. Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain. Mol. Neurobiol. doi:10.1007/s12035-012-8234-4 (2012) (Epub ahead of print).
38. Shiio Y, Aebersold R. Quantitative proteome analysis using isotope-coded affinity tags and 453 www.futuremedicine.com mass spectrometry. Nat. Protoc. 1(1), 139-145 (2006).
39. Thompson A, Schafer J, Kuhn K et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75(8), 1895-1904 (2003). (Pubitemid 36438013)
40. Guntert A, Campbell J, Saleem M et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J. Alzheimers Dis. 21(2), 585-596 (2010).
41. Antequera D, Vargas T, Ugalde C et al. Cytoplasmic gelsolin increases mitochondrial activity and reduces Abeta burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 36(1), 42-50 (2009).
42. Ji L, Chauhan A, Wegiel J, Essa MM, Chauhan V. Gelsolin is proteolytically cleaved in the brains of individuals with Alzheimer's disease. J. Alzheimers Dis. 18(1), 105-111 (2009).
43. Hirko AC, Meyer EM, King MA, Hughes JA. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol. Ther. 15(9), 1623-1629 (2007). (Pubitemid 47289005)
44. Chauhan V, Ji L, Chauhan A. Antiamyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology 9(6), 381-389 (2008).
45. Barba I, Fernandez-Montesinos R, Garcia-Dorado D, Pozo D. Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J. Cell. Mol. Med. 12(5 A), 1477-1485 (2008).
46. Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34(1), 173-186 (2009).
47. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35(2), 165-176 (2009).
48. Whiley L, Legido-Quigley C. Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease. Bioanalysis 3(10), 1121-1142 (2011).
49. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 30(7), 1235-1239 (2009).
50. Han X, Rozen S, Boyle SH et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6(7), e21643 (2011).
51. Li NJ, Liu WT, Li W et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 43(12), 992-997 (2010).
52. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol. Aging 31(1), 17-24 (2010).
53. Mielke MM, Haughey NJ, Bandaru VV et al. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J. Alzheimers Dis. 27(2), 259-269 (2011).
54. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J. Lipid Res. 53(3), 567-576 (2012).
55. Lawton KA, Berger A, Mitchell M et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 9(4), 383-397 (2008). (Pubitemid 351803924)
56. Han X, Gross RW. Shotgun lipidomics: multidimensional MS analysis of cellular lipidomes. Expert Rev. Proteomics 2(2), 253-264 (2005). (Pubitemid 40529863)
57. Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 24(3), 367-412 (2005). (Pubitemid 40665798)
58. Yang K, Cheng H, Gross RW, Han X. Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics. Anal. Chem. 81(11), 4356-4368 (2009).
59. Castillo S, Mattila I, Miettinen J, Oresic M, Hyotylainen T. Data analysis tool for comprehensive two-dimensional gas chromatography/time-of- flight mass spectrometry. Anal. Chem. 83(8), 3058-3067 (2011).
60. Nygren H, Seppanen-Laakso T, Castillo S, Hyotylainen T, Oresic M. Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. Methods Mol. Biol. 708, 247-257 (2011).
61. Orešic M, Hyötyläinen T, Herukka SK et al. Metabolome in progression to Alzheimer's disease. Transl. Psych. 1(12), e57 (2011).
62. Van Himbergen TM, Beiser AS, Ai M et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch. Neurol. 69(5), 594-600 (2012).
63. Marx CE, Trost WT, Shampine LJ et al. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol. Psychiatry 60(12), 1287-1294 (2006). (Pubitemid 44838538)
64. Smith CD, Wekstein DR, Markesbery WR, Frye CA. 3alpha, 5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology (Berl.) 186(3), 481-485 (2006). (Pubitemid 43800848)
65. Schenk S, Schoenhals GJ, De Souza G, Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC Med. Genomics 1, 41 (2008).
66. Qian WJ, Kaleta DT, Petritis BO et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol. Cell. Proteomics 7(10), 1963-1973 (2008).
67. Smith MP, Wood SL, Zougman A et al. A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics 11(11), 2222-2235 (2011).
68. Gold L, Ayers D, Bertino J et al. Aptamerbased multiplexed proteomic technology for biomarker discovery. PLoS One 5(12), e15004 (2010).
69. Hebert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 32(4), 199-206 (2009).
70. Hebert SS, Horre K, Nicolai L et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol. Dis. 33(3), 422-428 (2009).
71. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 18(3), 297-300 (2007).
72. Lukiw WJ, Dua P, Pogue AI, Eicken C, Hill JM. Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome. J. Toxicol. Environ. Health A 74(22-24), 1460-1468 (2011).
73. Carrascal M, Gay M, Ovelleiro D, Casas V, Gelpi E, Abian J. Characterization of the human plasma phosphoproteome using linear ion trap mass spectrometry and multiple search engines. J. Proteome Res. 9(2), 876-884 (2010).
74. Butterfield DA. Oxidative stress in neurodegenerative disorders. Antioxid. Redox Signal. 8(11-12), 1971-1973 (2006). (Pubitemid 46499263)
75. Butterfield DA, Gnjec A, Poon HF et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 10(4), 391-397 (2006).
76. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur. J. Pharmacol. 545(1), 39-50 (2006). (Pubitemid 44215876)
77. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. NY Acad. Sci. 1147, 70-78 (2008).
78. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 29(12), 609-615 (2008).
79. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37(2), 289-305 (2005). (Pubitemid 39330191)
80. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293(5), 1566-1570 (2002). (Pubitemid 34681057)
81. Di Domenico F, Coccia R, Butterfield DA, Perluigi M. Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim. Biophys. Acta 1814(12), 1785-1795 (2011).
82. Yu HL, Chertkow HM, Bergman H, Schipper HM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3(11), 2240-2248 (2003). (Pubitemid 37414088)
83. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6(12), 2212-2229 (2007).
84. Thambisetty M, Simmons A, Hye A et al. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 6(12), e28527 (2011).
85. Thambisetty M, Simmons A, Velayudhan L et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 67(7), 739-748 (2010).
86. Thambisetty M, An Y, Kinsey A et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59(1), 212-217 (2012).
87. Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41(10), 1088-1093 (2009).
88. Lambert JC, Heath S, Even G et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41(10), 1094-1099 (2009).
89. Erk S, Meyer-Lindenberg A, Opitz Von Boberfeld C et al. Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. J. Neurosci. 31(49), 18180-18184 (2011).
90. Bettens K, Brouwers N, Engelborghs S et al. Both common variations and rare nonsynonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol. Neurodegener. 7, 3 (2012).
91. Furney SJ, Kronenberg D, Simmons A et al. Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease - cytokines and MRI measures together predict disease progression. J. Alzheimers Dis. 26(Suppl. 3), 395-405 (2011).
92. Silliman CC, Dzieciatkowska M, Moore EE et al. Proteomic analyses of human plasma: Venus versus Mars. Transfusion 52(2), 417-424 (2012).
93. Teunissen CE, Petzold A, Bennett JL et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22), 1914-1922 (2009).
94. Luque-Garcia JL, Neubert TA. Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J. Chromatogr. A 1153(1-2), 259-276 (2007). (Pubitemid 46755182)
95. Yang E, Farnum M, Lobanov V et al. Quantifying the pathophysiological timeline of Alzheimer's disease. J. Alzheimers Dis. 26(4), 745-753 (2011). Describes a synchronization model to predict disease stages.
96. Marksteiner J, Kemmler G, Weiss EM et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 32(3), 539-540 (2011).
97. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 7(1), e29868 (2012).
98. de Paula MR, Ravetti MG, Berretta R, Moscato P. Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease. PLoS One 6(3), e17481 (2011).